CoChat

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe

Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O’Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., for the ADOPT Study Group · 2006 · Diabetic Medicine
Cited by 56

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims To examine baseline characteristics of patients recruited into ADOPT, a multinational trial comparing three oral glucose‐lowering monotherapies. Methods Between April 2000 and June 2002, 4360 patients aged 30–75 years with Type 2 diabetes diagnosed for < 3 years and remaining on diet therapy alone with fasting plasma glucose levels (FPG) between 7.0 and 10.0 mmol/l were enrolled by 488 North American and European centres. Medical histories, anthropometric data and laboratory measurements were determined using common methodologies. Results The mean (sd) age of the patients was 57 (10) years, body mass index 32.2 (6.4) kg/m 2, HbA 1c 7.4 (0.9)%; 58% were male, 88% Caucasian and 15% smoked. North American Caucasians (NAC) were younger, more obese, and more insulin resistant than European Caucasians (EUC), but had better pancreatic B‐cell function. NAC had lower total, low‐density lipoprotein‐ and high‐density liporpotein‐cholesterol concentrations with higher triglyceride concentrations and were more often on lipid‐lowering treatment. They had lower blood pressure levels but were equally likely to be on antihypertensive treatment. Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC. Within North America, NAC had lower HbA 1c concentrations than Blacks, Hispanics and Asians despite similar or higher FPG and 30‐min postchallenge glucose concentrations. Conclusions Caucasian North American and European ADOPT patients differ with respect to adiposity, insulin resistance and metabolic syndrome prevalence. North American Blacks, Hispanics and Asians had lower HbA 1c concentrations than NAC despite similar or higher glucose concentrations. These phenotypic differences may influence the progression of Type 2 diabetes and the response to initial oral glucose‐lowering monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2006.02022.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 56

Metadata

Authors
Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O’Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., & for the ADOPT Study Group
Venue
Diabetic Medicine
Publisher
Wiley
Published
2006-11-17
Volume
23
Issue
12
Pages
1289-1294
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2023271144
Cited by
56
References
3
FWCI
3.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. https://app.cochat.ai/papers/10.1111/j.1464-5491.2006.02022.x
The paper
Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O’Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., & for the ADOPT Study Group. (2006). A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2006.02022.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.